Copper-tripeptide vial for skin, hair, and regeneration research. Lyophilized 50mg format.
Buy Reta UAE 30mg Pen, review live UAE quantity tiers from AED 1,500 per pen, and move directly to the secure order flow with batch RETP002 and published Janoshik documentation.
For batch proof, open the published Janoshik COA; for pen-duration planning, use the calculator; Retatrutide UAE. Updated April 22, 2026.
Retatrutide must not be frozen and should be protected from light to preserve documented storage conditions.
This is the fastest route for the Reta UAE 30mg Pen: confirm batch RETP002, review UAE delivery timing, choose a quantity tier, and continue to the secure order page. If you are comparing formats first, use the UAE overview; if you only need batch proof, open the COA library.
The 30mg pen and a BPC-157 vial are the most-paired items in the catalog. Add both to the cart in one click.
Many research teams still work from lyophilised powder, separate reconstitution steps, and manual measuring workflows. The Reta UAE 30mg Pen is a stabilised prefilled device — ready for pen-based dose setting without a mixing step. This page covers product format, batch documentation, and handling notes. For schedule rules, see the dosage guide; for mg-to-click lookup, the pen clicks chart; for batch documentation, the COA library; for all Retatrutide UAE formats and pricing, use the consolidated UAE supply page.
Retatrutide is classified as a tri-agonist, meaning it interacts with three distinct hormone receptors — GLP-1, GIP, and glucagon — rather than one or two. That broader receptor profile is the main reason it is tracked alongside semaglutide and tirzepatide in comparative research.
In the Phase 2 dataset, retatrutide produced a mean body-weight change of 24.2% at the 12mg weekly dose after 48 weeks, and a 2.2% HbA1c reduction was reported in participants with type 2 diabetes after 36 weeks. Additional subgroup analyses reported liver-fat and cardiometabolic marker changes. Ongoing Phase 3 trials are intended to clarify how those signals hold up in larger populations.
Unlike lyophilised powder formats that require separate reconstitution, the Retatrutide Pen removes that extra mixing step. The stabilised solution is pre-mixed, pH-balanced, and ready for pen-based dose setting when it arrives.
Each click of the pen mechanism delivers a precise 0.1mg dose, allowing researchers to document repeatable quantities across study protocols without weighing or separate volumetric measurement. Published trial protocols use subcutaneous administration; see the retatrutide dosage guide for the full titration schedule and the calculator for pen-duration planning.
When teams review retatrutide for metabolic research, the practical questions usually center on published adverse-event patterns, concurrent compound considerations, and storage discipline. As a triple-agonist peptide developed by Eli Lilly, retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, which is why it is tracked separately from single-pathway and dual-pathway compounds.
Clinical trials of retatrutide have reported gastrointestinal symptoms such as nausea, diarrhoea, and occasional vomiting most often during dose escalation. Published summaries generally describe those events as mild to moderate. Following the published dosing guidance and titration rules helps keep those observations in the right protocol context.
Because retatrutide influences glucose metabolism through GLP-1, GIP, and glucagon receptor activity, it may interact with other compounds that affect glycaemic control or appetite signalling. Research teams should document concurrent compounds carefully so those variables are visible in protocol analysis.
Proper storage remains central to reliable handling. The prefilled pen should be kept refrigerated at 2–8°C, protected from light, and never frozen. Remy Peptides provides UAE fulfilment support, and each batch includes Janoshik Analytical documentation for ≥99.2% purity.
It is important to note that retatrutide is still undergoing clinical trials and is not approved for human consumption. All products are supplied strictly for research purposes, and researchers should follow established protocols and safety guidelines when handling peptides in the laboratory.
Retatrutide's three-receptor mechanism is the reason it remains one of the most closely watched compounds in the metabolic pipeline. The published Phase 2 dataset reported strong weight-change and glycaemic signals, but the compound remains investigational and should be read through trial data, protocol rules, and storage discipline rather than marketing language. Use the dosage calculator for protocol planning.
Every batch is independently tested by Janoshik Analytical — a leading third-party laboratory specialising in pharmaceutical purity analysis. Full test reports are included with every order.
Retatrutide (LY-3437943) is a triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1, GIP, and GCGR. In published research, that mechanism is being studied for its effects on appetite signalling, glucose handling, and energy expenditure. Learn more about the current approval status.
In the Phase 2 trial, retatrutide produced a mean body-weight change of 24.2% at the 12mg weekly dose after 48 weeks, and a 2.2% HbA1c reduction was reported in participants with type 2 diabetes after 36 weeks. Track the latest results at the TRIUMPH trial tracker.
The most common side effects reported in clinical trials are gastrointestinal symptoms including nausea, diarrhoea, and occasional vomiting, most often during dose escalation. Published summaries generally describe those events as mild to moderate. Starting with lower doses and following the published titration schedule helps keep those observations in context. See the full side effects profile.
The Reta UAE 30mg Pen is a prefilled Pen containing a stabilized, pH-balanced solution that requires no reconstitution. Unlike lyophilized powder formats that need syringes, sterile water, and sterile technique — increasing contamination and dosing error risk — the pen delivers precise 0.1mg-per-click dosing with 300 clicks per pen. Each pen includes 20 pen needles (31G, 5mm) and a Certificate of Analysis. Read the full pen usage guide.
The Retatrutide Pen should be stored refrigerated at 2–8°C, protected from light, and never frozen. Maintaining documented cold-chain conditions helps preserve consistent handling and storage records from supplier to laboratory. Remy Peptides ships with cold-chain packaging and UAE fulfilment support where available.
As of 2026, retatrutide is not FDA approved. It is currently in Phase 3 clinical trials (TRIUMPH program) conducted by Eli Lilly, being investigated for chronic weight management, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD). All Remy Peptides products are supplied strictly for in-vitro research use only, not for human consumption. See the full approval status breakdown.
The 30mg FlexiPen is the full-size format. Smaller 10mg, 20mg, and 40mg vials are in the catalog too, for labs that reconstitute their own.
10mg lyophilized vial · triple-agonist LY-3437943 · cold-chain
40mg lyophilized vial · triple-agonist LY-3437943 · cold-chain
Browse research stacks → — the flagship pen pairs with BPC-157 in the Pen + BPC Pair at 5% off.
